320 related articles for article (PubMed ID: 36349732)
1. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.
Amangurbanova M; Huang DQ; Loomba R
Aliment Pharmacol Ther; 2023 Jan; 57(1):37-51. PubMed ID: 36349732
[TBL] [Abstract][Full Text] [Related]
2. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
3. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
4. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
5. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
[TBL] [Abstract][Full Text] [Related]
6. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
7. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
9. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of
Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
[TBL] [Abstract][Full Text] [Related]
11. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
[TBL] [Abstract][Full Text] [Related]
12. Expression and localization of HSD17B13 along mouse urinary tract.
Zhang H; Chang J; Dai Z; Wang Q; Qiao R; Huang Y; Ma B; Jiang J; Zhu C; Su W; Zhang X; Guan Y
Am J Physiol Renal Physiol; 2024 May; ():. PubMed ID: 38779753
[TBL] [Abstract][Full Text] [Related]
13. HSD17B13: A Potential Therapeutic Target for NAFLD.
Zhang HB; Su W; Xu H; Zhang XY; Guan YF
Front Mol Biosci; 2021; 8():824776. PubMed ID: 35071330
[TBL] [Abstract][Full Text] [Related]
14.
Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
[TBL] [Abstract][Full Text] [Related]
16. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.
Ching-Yeung Yu B; Kwok D; Wong VW
J Clin Exp Hepatol; 2019; 9(4):491-496. PubMed ID: 31516265
[TBL] [Abstract][Full Text] [Related]
17. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target.
Motomura T; Amirneni S; Diaz-Aragon R; Faccioli LAP; Malizio MR; Coard MC; Kocas-Kilicarslan ZN; Frau C; Haep N; Ostrowska A; Florentino RM; Soto-Gutierrez A
J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34208839
[TBL] [Abstract][Full Text] [Related]
18. Role of HSD17B13 in the liver physiology and pathophysiology.
Su W; Mao Z; Liu Y; Zhang X; Zhang W; Gustafsson JA; Guan Y
Mol Cell Endocrinol; 2019 Jun; 489():119-125. PubMed ID: 30365983
[TBL] [Abstract][Full Text] [Related]
19. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
Wang M; Li J; Li H; Dong B; Jiang J; Liu N; Tan J; Wang X; Lei L; Li H; Sun H; Tang M; Wang H; Yan H; Li Y; Jiang J; Peng Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628360
[TBL] [Abstract][Full Text] [Related]
20. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]